THJ-2201

THJ-2201 is a synthetic cannabinoid that is the indazole analogue of AM-2201. It was first identified in illegal herbal products in Japan in 2013. It is presumed to be a potent agonist of the CB1 receptor, although it is unclear whether it is selective for this target. THJ-2201 is an Anlage II controlled substance in Germany as of May 2015. It is also banned in Sweden.

Chemistry

THJ-2201 is a synthetic cannabinoid that is the indazole analogue of AM-2201. It is structurally related to other synthetic cannabinoids including AM-2201, AM-2233, and AB-PINACA. The systematic name of THJ-2201 is naphthalen-1-yl(1-(5-fluoropentyl)-1H-indazol-3-yl)-methanone.

Pharmacology

THJ-2201 is presumed to be a potent agonist of the CB1 receptor, although it is unclear whether it is selective for this target. Synthetic cannabinoids such as THJ-2201 are often used in research to study the endocannabinoid system.

Legal status

THJ-2201 is an Anlage II controlled substance in Germany as of May 2015. It is also banned in Sweden. The legal status of THJ-2201 in other countries is unclear, but it may be controlled under analogue laws in countries such as the United States.

See also

• AM-2201
• AM-2233
• AB-PINACA
• Synthetic cannabinoids
• CB1 receptor

THJ-2201 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski